A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Raxatrigine (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms RELAY-1
  • Sponsors Biogen; Convergence Pharmaceuticals
  • Most Recent Events

    • 04 Apr 2017 Planned End Date changed from 1 Dec 2017 to 15 Dec 2017.
    • 04 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 15 Dec 2017.
    • 03 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top